Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-929P is a processed pseudogene derived from the U6 small nuclear RNA gene family[4][5]. U6 small nuclear RNA is a crucial component of the spliceosome, the cellular complex responsible for the excision of introns from pre-mRNA, a key step in gene expression[1][3]. However, as a pseudogene, RNU6-929P does not encode a functional RNA or protein and is generally presumed non-functional. Pseudogenes like RNU6-929P arise via retrotransposition or gene duplication followed by mutational inactivation, and although some pseudogenes have regulatory or biomarker roles, there is no specific evidence for RNU6-929P in this context[2][4][5]. In summary, RNU6-929P is a non-coding, non-functional RNA pseudogene with no known direct biological or disease-related roles and is not considered a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 929, pseudogene (RNU6-929P).